Model external funding, pool execution and operating requirements. Founder contribution: $0. This page accepts no funds.
Scenario inputs only. The reserve is an assumption; actual bonds and operating costs need verification. Deployment gas also requires an ETH sponsor.
Saves JSON to your device. No submission, pledge or wallet transaction.A neutral 50¢ opening inventory price and the native 50-bps smaller-leg fee fixture are used here. These are illustrations, not clinical probabilities or approved live terms.
Native integer constant-product illustration; fees stay outside reserves. Excludes gas, oracle costs and other trades. No APY, return guarantee, token subsidy or leverage is assumed.
October 28, 2026 source snapshot. These are unlisted candidates with $0 committed. Rank reflects editorial suitability, not measured demand; status and final rules need review.
Intellia Therapeutics · hereditary angioedema
In vivo CRISPR regulatory milestone; recognizable gene-editing theme. Demand is a hypothesis, not measured.
Novel modality raises safety and interpretation risk; exact approved population must be pinned.
Belite Bio · Stargardt disease type 1
Single named rare-eye-disease NDA; accessible binary regulatory question.
Pin age range, indication and approval definition; do not confuse US decision with Japanese or Access Consortium submissions.
Dyne Therapeutics · Duchenne muscular dystrophy amenable to exon 51 skipping
Priority-reviewed DMD BLA with an explicit target; catalyst soon enough to test retention.
Accelerated approval based on surrogate endpoint needs explicit treatment; skip if safe release cannot precede target with useful lead time.
Axsome Therapeutics · cataplexy in narcolepsy
Specific CNS NDA with long preparation runway; substitute for DYN if launch slips.
Longer capital lock-up; approval of another Axsome product cannot satisfy this question.
BridgeBio Pharma · autosomal dominant hypocalcemia type 1 (ADH1)
Genetic-disease franchise and clear NDA target; differentiated from first basket.
Issuer has multiple regulatory programs; May 8 date is encaleret, not oral infigratinib or BBP-418.
Exelixis · metastatic colorectal cancer
Oncology catalyst with public extension history; useful independent regulatory category.
Old December 3 2026 date is superseded; combination and treatment line must match final resolution text.
Pharvaris · on-demand treatment of hereditary angioedema attacks
Oral HAE treatment is explainable to traders; useful later comparable to gene editing.
HAE economic theme overlaps NTLA; avoid correlated concentration and do not confuse IR with XR prophylaxis.
Inhibrx Biosciences · unresectable or metastatic conventional chondrosarcoma
Named BLA in rare oncology indication with an explicit target.
Distinguish conventional histology and disease stage; review updated safety and any changed FDA timetable before publication.
Unicycive Therapeutics · hyperphosphatemia in chronic kidney disease patients on dialysis
Fresh NDA resubmission target; manufacturing-versus-efficacy distinction can support research content.
Prior CRLs and third-party manufacturing inspections make timing discontinuous; target may accelerate or slip.
Gilead Sciences · HIV pre-exposure prophylaxis
Broadly recognizable HIV-prevention franchise; diversifies small biotech concentration.
Existing twice-yearly injectable approval is not approval of this weekly oral formulation; ticker stock hedge is especially noisy.
These dates provide no official time or approved market resolution deadline.
Planning only. No release or capital allocation is approved through this page.